Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎ New York, NY
(646) 856-9261
info@inspirna.com

Clinical Advisors

Co-founder & Chair of Scientific Advisory Board
Sohail Tavazoie, M.D., Ph.D.

Dr. Sohail Tavazoie is the Leon Hess Professor, Howard Hughes Medical Institute Faculty Scholar and Head of the Meyer Laboratory of Systems Cancer Biology at The Rockefeller University.

Advisor
Antoni Ribas, M.D., Ph.D.

Dr. Antoni Ribas, M.D., Ph.D. is Professor of Medicine, Professor of Surgery, and Professor of Molecular and Medical Pharmacology at the University of California Los Angeles.

Advisor
Yelena Janjigian, M.D.

Dr. Yelena Y. Janjigian is a medical oncologist and Chief of the Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center.

Advisor
Hossein Borghaei, D.O., M.S.

Dr. Borghaei is the Chief of Thoracic Medical Oncology and Professor, Department of Oncology/Hematology, Co-Director, Immune Monitoring Facility at Fox Chase Cancer Center in Philadelphia, PA.

Advisor
Jean-Pierre Bizzari, M.D.

Jean-Pierre brings over 30 years of academic and industry experience in oncology drug development.

Advisor
Josep Tabernero, M.D., Ph.D.

Josep Tabernero, M.D., Ph.D. is the Director of the Vall d’Hebron Institute of Oncology (VHIO) and Head of the Medical Oncology Department of Vall d’Hebron University Hospital.

Advisor
Alan P. Venook, M.D.

Alan P. Venook, M.D. is the Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California (UCSF) San Francisco and the Shorenstein Associate Director for Program Development at the UCSF Helen Diller Family Comprehensive Cancer Center.